Endo Int'l Plc (ENDP) 19.82 $ENDP Endo Pharmace
Post# of 273330
Posted On: 09/03/2016 1:06:04 AM
Endo Int'l Plc (ENDP) 19.82 $ENDP
Endo Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.26%
Comtex SmarTrend(R) - Fri Sep 02, 12:51PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $19.21 to a high of $20.58. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $20.12 on volume of 6.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 19.82 (-0.41)
Look for Shares of Endo Pharmaceuticals to Potentially Rebound after Yesterday's 1.24% Sell Off
Comtex SmarTrend(R) - Mon Aug 29, 1:09PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $20.30 to a high of $21.21. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $20.67 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 19.82 (-0.41)
Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 31.79 (-1.58), ENDP: 19.82 (-0.41), VRX: 28.76 (-0.36), BSTC: 36.56 (-0.99), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32), USNA: 138.16 (+1.81)
Stock Market News for August 26, 2016
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:09AM CDT
Benchmarks finished in the red on Thursday as investors refrained from making big bets ahead of Fed Chief Janet Yellen’s speech at Jackson Hole, Wyoming today
MNK: 72.42 (-3.17), TSLA: 197.78 (-2.99), ENDP: 19.82 (-0.41), F: 12.50 (+0.06), MDT: 87.32 (+0.34), GME: 28.39 (+0.36), MYL: 39.97 (-1.95), PDCO: 46.89 (+0.86), TIF: 70.08 (-0.29), BA: 131.16 (+1.26), ESRX: 72.54 (+0.32), STJ: 78.65 (+0.51), SSYS: 21.93 (+0.60), TECD: 73.33 (-0.01), ADSK: 68.01 (+0.64)
26.1% Return Seen to Date on SmarTrend Endo Pharmaceuticals Call (ENDP)
Comtex SmarTrend(R) - Thu Aug 25, 1:38PM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on June 3rd, 2016 at $17.35. In approximately 3 months, Endo Pharmaceuticals has returned 26.09% as of today's recent price of $21.87.
ENDP: 19.82 (-0.41)
Look for Shares of Endo Pharmaceuticals to Potentially Pullback after Yesterday's 2.48% Rise
Comtex SmarTrend(R) - Tue Aug 23, 2:31PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $22.90 to a high of $23.79. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $23.35 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ENDP: 19.82 (-0.41)
Endo's President and CEO Adopts 10b5-1 Trading Plan
PR Newswire Europe - Thu Aug 18, 3:05PM CDT
Endo International plc today announced that Rajiv De Silva, President and CEO, has entered into a Rule 10b5-1 stock trading plan in connection with his year-end tax planning. Under the terms of Mr. De Silva's stock trading plan, an authorized third-party broker will sell up to 13,500 Endo shares beneficially owned by Mr. De Silva, which represents approximately 4 percent of Mr. De Silva's total Endo stock ownership. The stock trading plan will be completed in September 2016. If all of the planned Endo share sales under Mr. De Silva's stock trading plan are completed, Mr. De Silva will continue to beneficially own Endo shares with an aggregate market value well in excess of five times his base salary, as required by the Company's stock ownership guidelines.
ENDP: 19.82 (-0.41), ENL.TO: 26.37 (-0.08)
Endo Pharmaceuticals Shares Up 31.1% Since SmarTrend's Buy Recommendation (ENDP)
Comtex SmarTrend(R) - Thu Aug 18, 12:58AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on June 3rd, 2016 at $17.35. In approximately 3 months, Endo Pharmaceuticals has returned 31.10% as of today's recent price of $22.74.
ENDP: 19.82 (-0.41)
Endo (ENDP) Withdraws Label Expansion Filing for Opana ER
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 3:48PM CDT
Endo International (ENDP) announced that after discussions with the FDA the company has decided to withdraw its supplemental new drug application for Opana ER.
ENDP: 19.82 (-0.41), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Under Armour trade offers a 5% return in 32 days, or find similar option trades on Endo International, Sears Holdings, Celgene, and Barrick Gold Corporation
PR Newswire - Mon Aug 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABX, CELG, ENDP, SHLD, and UA.
UA: 38.56 (-1.19), ENDP: 19.82 (-0.41), ABX: 18.16 (+0.36), SHLD: 13.33 (-0.16), CELG: 105.49 (-0.88)
Global Testosterone Replacement Therapy Market to Grow 3.35% by 2020 - Entry of SARMs - Key Vendors are AbbVie, Allergan & Endo Pharmaceuticals - Research and Markets
BusinessWire - Fri Aug 12, 11:49AM CDT
Research and Markets has announced the addition of the "Global Testosterone Replacement Therapy Market 2016-2020" report to their offering.
AGN: 235.96 (-1.80), ENDP: 19.82 (-0.41)
Endo Announces OPANA® ER Regulatory Update
PR Newswire Europe - Fri Aug 12, 6:01AM CDT
DUBLIN, Aug. 12, 2016 /PRNewswire/ -- Endo International plc announced today that based on an August 11, 2016 discussion with the U.S. Food and Drug Administration (FDA), the Company has decided to withdraw its supplemental New Drug Application (sNDA) relating to specific abuse deterrent labeling for OPANA(R) ER without prejudice to re-filing. The Company plans to continue collecting and analyzing epidemiological data relating to OPANA(R) ER. Endo's financial projections for 2016 did not assume approval of the sNDA.
ENDP: 19.82 (-0.41), ENL.TO: 26.37 (-0.08)
BioDelivery (BDSI) Q2 Loss Meets Estimates, Revenues Up
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 7:52AM CDT
BioDelivery (BDSI) reported a loss of 31 cents in second-quarter of 2016 inline with the Zacks Consensus Estimate.
BDSI: 2.43 (-0.02), ENDP: 19.82 (-0.41), GERN: 2.75 (+0.02), COLL: 8.98 (+0.15)
Endo Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.26%
Comtex SmarTrend(R) - Fri Sep 02, 12:51PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $19.21 to a high of $20.58. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $20.12 on volume of 6.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 19.82 (-0.41)
Look for Shares of Endo Pharmaceuticals to Potentially Rebound after Yesterday's 1.24% Sell Off
Comtex SmarTrend(R) - Mon Aug 29, 1:09PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $20.30 to a high of $21.21. Yesterday, the shares fell 1.2%, which took the trading range below the 3-day low of $20.67 on volume of 2.8 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ENDP: 19.82 (-0.41)
Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 31.79 (-1.58), ENDP: 19.82 (-0.41), VRX: 28.76 (-0.36), BSTC: 36.56 (-0.99), MYL: 39.97 (-1.95), TEVA: 51.22 (+0.32), USNA: 138.16 (+1.81)
Stock Market News for August 26, 2016
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 9:09AM CDT
Benchmarks finished in the red on Thursday as investors refrained from making big bets ahead of Fed Chief Janet Yellen’s speech at Jackson Hole, Wyoming today
MNK: 72.42 (-3.17), TSLA: 197.78 (-2.99), ENDP: 19.82 (-0.41), F: 12.50 (+0.06), MDT: 87.32 (+0.34), GME: 28.39 (+0.36), MYL: 39.97 (-1.95), PDCO: 46.89 (+0.86), TIF: 70.08 (-0.29), BA: 131.16 (+1.26), ESRX: 72.54 (+0.32), STJ: 78.65 (+0.51), SSYS: 21.93 (+0.60), TECD: 73.33 (-0.01), ADSK: 68.01 (+0.64)
26.1% Return Seen to Date on SmarTrend Endo Pharmaceuticals Call (ENDP)
Comtex SmarTrend(R) - Thu Aug 25, 1:38PM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on June 3rd, 2016 at $17.35. In approximately 3 months, Endo Pharmaceuticals has returned 26.09% as of today's recent price of $21.87.
ENDP: 19.82 (-0.41)
Look for Shares of Endo Pharmaceuticals to Potentially Pullback after Yesterday's 2.48% Rise
Comtex SmarTrend(R) - Tue Aug 23, 2:31PM CDT
Endo Pharmaceuticals (NASDAQ:ENDP) traded in a range yesterday that spanned from a low of $22.90 to a high of $23.79. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $23.35 on volume of 2.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
ENDP: 19.82 (-0.41)
Endo's President and CEO Adopts 10b5-1 Trading Plan
PR Newswire Europe - Thu Aug 18, 3:05PM CDT
Endo International plc today announced that Rajiv De Silva, President and CEO, has entered into a Rule 10b5-1 stock trading plan in connection with his year-end tax planning. Under the terms of Mr. De Silva's stock trading plan, an authorized third-party broker will sell up to 13,500 Endo shares beneficially owned by Mr. De Silva, which represents approximately 4 percent of Mr. De Silva's total Endo stock ownership. The stock trading plan will be completed in September 2016. If all of the planned Endo share sales under Mr. De Silva's stock trading plan are completed, Mr. De Silva will continue to beneficially own Endo shares with an aggregate market value well in excess of five times his base salary, as required by the Company's stock ownership guidelines.
ENDP: 19.82 (-0.41), ENL.TO: 26.37 (-0.08)
Endo Pharmaceuticals Shares Up 31.1% Since SmarTrend's Buy Recommendation (ENDP)
Comtex SmarTrend(R) - Thu Aug 18, 12:58AM CDT
SmarTrend identified an Uptrend for Endo Pharmaceuticals (NASDAQ:ENDP) on June 3rd, 2016 at $17.35. In approximately 3 months, Endo Pharmaceuticals has returned 31.10% as of today's recent price of $22.74.
ENDP: 19.82 (-0.41)
Endo (ENDP) Withdraws Label Expansion Filing for Opana ER
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 3:48PM CDT
Endo International (ENDP) announced that after discussions with the FDA the company has decided to withdraw its supplemental new drug application for Opana ER.
ENDP: 19.82 (-0.41), CORT: 5.31 (-0.04), PCRX: 39.04 (-1.33)
Under Armour trade offers a 5% return in 32 days, or find similar option trades on Endo International, Sears Holdings, Celgene, and Barrick Gold Corporation
PR Newswire - Mon Aug 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABX, CELG, ENDP, SHLD, and UA.
UA: 38.56 (-1.19), ENDP: 19.82 (-0.41), ABX: 18.16 (+0.36), SHLD: 13.33 (-0.16), CELG: 105.49 (-0.88)
Global Testosterone Replacement Therapy Market to Grow 3.35% by 2020 - Entry of SARMs - Key Vendors are AbbVie, Allergan & Endo Pharmaceuticals - Research and Markets
BusinessWire - Fri Aug 12, 11:49AM CDT
Research and Markets has announced the addition of the "Global Testosterone Replacement Therapy Market 2016-2020" report to their offering.
AGN: 235.96 (-1.80), ENDP: 19.82 (-0.41)
Endo Announces OPANA® ER Regulatory Update
PR Newswire Europe - Fri Aug 12, 6:01AM CDT
DUBLIN, Aug. 12, 2016 /PRNewswire/ -- Endo International plc announced today that based on an August 11, 2016 discussion with the U.S. Food and Drug Administration (FDA), the Company has decided to withdraw its supplemental New Drug Application (sNDA) relating to specific abuse deterrent labeling for OPANA(R) ER without prejudice to re-filing. The Company plans to continue collecting and analyzing epidemiological data relating to OPANA(R) ER. Endo's financial projections for 2016 did not assume approval of the sNDA.
ENDP: 19.82 (-0.41), ENL.TO: 26.37 (-0.08)
BioDelivery (BDSI) Q2 Loss Meets Estimates, Revenues Up
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 7:52AM CDT
BioDelivery (BDSI) reported a loss of 31 cents in second-quarter of 2016 inline with the Zacks Consensus Estimate.
BDSI: 2.43 (-0.02), ENDP: 19.82 (-0.41), GERN: 2.75 (+0.02), COLL: 8.98 (+0.15)
(0)
(0)